---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-001681"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:11:33.987723+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1

## Summary
- Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.
- Cash at year-end totaled $13.1 million, expected to fund operations and pipeline development.
- Royalty payments from Takeda sublicense were ~$1.7M, up 47.1% YoY.
- DNase oncology platform progressing towards first-in-human study combined with checkpoint inhibitors or chemo.
- Appointed oncology and NETs experts Allan Tsung, MD and Jonathan Spicer, MD, PhD to Scientific Advisory Board.

## SEC filing metadata
- accession: 0001683168-23-001681
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/0001683168-23-001681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/xenetic_8k-032323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-001681
- JSON: https://secwatch.observer/filing/0001683168-23-001681.json
- Plain text: https://secwatch.observer/filing/0001683168-23-001681.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported the full year 2022 results: net income Net loss for the year ended December 31, 2022 was approximately $6.6 million..
  - Period: the full year 2022
  - Net income: Net loss for the year ended December 31, 2022 was approximately $6.6 million.
  - Result: reported results
  source text: On March 23, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the year ended December 31, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/0001683168-23-001681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.